Published in Proc Natl Acad Sci U S A on February 17, 2012
Influence of GluN2 subunit identity on NMDA receptor function. Neuropharmacology (2013) 1.07
Genetic KCa3.1-deficiency produces locomotor hyperactivity and alterations in cerebral monoamine levels. PLoS One (2012) 0.94
Mechanistic basis of MAGUK-organized complexes in synaptic development and signalling. Nat Rev Neurosci (2016) 0.87
Design and characterization of bivalent BET inhibitors. Nat Chem Biol (2016) 0.86
Membrane-permeable C-terminal dopamine transporter peptides attenuate amphetamine-evoked dopamine release. J Biol Chem (2013) 0.85
Genetic ablation of soluble tumor necrosis factor with preservation of membrane tumor necrosis factor is associated with neuroprotection after focal cerebral ischemia. J Cereb Blood Flow Metab (2015) 0.84
Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS. Br J Pharmacol (2015) 0.83
The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Curr Neuropharmacol (2014) 0.82
Progressive brain damage, synaptic reorganization and NMDA activation in a model of epileptogenic cortical dysplasia. PLoS One (2014) 0.80
Efficacy of the PSD95 inhibitor Tat-NR2B9c in mice requires dose translation between species. J Cereb Blood Flow Metab (2015) 0.79
Protein kinase A-phosphorylated KV1 channels in PSD95 signaling complex contribute to the resting membrane potential and diameter of cerebral arteries. Circ Res (2014) 0.79
Endogenous IFN-β signaling exerts anti-inflammatory actions in experimentally induced focal cerebral ischemia. J Neuroinflammation (2015) 0.79
Novel microscale approaches for easy, rapid determination of protein stability in academic and commercial settings. Biochim Biophys Acta (2014) 0.79
Biochemical investigations of the mechanism of action of small molecules ZL006 and IC87201 as potential inhibitors of the nNOS-PDZ/PSD-95-PDZ interactions. Sci Rep (2015) 0.78
Cell therapy centered on IL-1Ra is neuroprotective in experimental stroke. Acta Neuropathol (2016) 0.78
Scaffolding protein Homer1a protects against NMDA-induced neuronal injury. Cell Death Dis (2015) 0.78
Organization and functions of mGlu and GABAB receptor complexes. Nature (2016) 0.77
Design of a PDZbody, a bivalent binder of the E6 protein from human papillomavirus. Sci Rep (2015) 0.77
Simultaneous prediction of binding free energy and specificity for PDZ domain-peptide interactions. J Comput Aided Mol Des (2013) 0.76
To serve and neuroprotect. Nat Med (2012) 0.76
Novel drug target identification for the treatment of dementia using multi-relational association mining. Sci Rep (2015) 0.75
Targeting protein-protein interactions with trimeric ligands: high affinity inhibitors of the MAGUK protein family. PLoS One (2015) 0.75
Reconstitution of multivalent PDZ domain binding to the scaffold protein PSD-95 reveals ternary-complex specificity of combinatorial inhibition. Structure (2014) 0.75
NOS knockout or inhibition but not disrupting PSD-95-NOS interaction protect against ischemic brain damage. J Cereb Blood Flow Metab (2016) 0.75
Stroke: Can PSD95 inhibitors widen the therapeutic window? Nat Rev Drug Discov (2012) 0.75
Targeting a Potassium Channel/Syntaxin Interaction Ameliorates Cell Death in Ischemic Stroke. J Neurosci (2017) 0.75
Effects of Dimeric PSD-95 Inhibition on Excitotoxic Cell Death and Outcome After Controlled Cortical Impact in Rats. Neurochem Res (2017) 0.75
In vivo protein transduction: delivery of a biologically active protein into the mouse. Science (1999) 10.70
Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell (2010) 7.52
Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ. Cell (1996) 6.87
The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U S A (2000) 5.81
Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci U S A (1991) 5.70
Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science (1994) 5.15
Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science (2002) 3.98
Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science (1999) 3.23
Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology (2008) 3.04
Quaternary structure, protein dynamics, and synaptic function of SAP97 controlled by L27 domain interactions. Neuron (2004) 2.49
PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J Biol Chem (1999) 2.42
Organization and dynamics of PDZ-domain-related supramodules in the postsynaptic density. Nat Rev Neurosci (2009) 2.22
Microglia protect neurons against ischemia by synthesis of tumor necrosis factor. J Neurosci (2009) 1.97
Making protein interactions druggable: targeting PDZ domains. Nat Rev Drug Discov (2004) 1.73
Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles. Neuropsychopharmacology (2008) 1.68
Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. J Neurosci (2008) 1.58
Supramodular structure and synergistic target binding of the N-terminal tandem PDZ domains of PSD-95. J Mol Biol (2003) 1.45
Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand. J Biomol Screen (2003) 1.38
Evolution of brain infarction after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab (2000) 1.32
Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat. Stroke (2008) 1.31
Biomimetic divalent ligands for the acute disruption of synaptic AMPAR stabilization. Nat Chem Biol (2010) 1.18
Functional mapping of the motor cortex of the white mouse by a microstimulation method. Neurosci Behav Physiol (1998) 1.12
Emerging mechanisms of disrupted cellular signaling in brain ischemia. Nat Neurosci (2011) 1.11
Dynamics of regional brain metabolism and gene expression after middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab (2000) 1.10
Unbiased cell quantification reveals a continued increase in the number of neocortical neurones during early post-natal development in mice. Eur J Neurosci (2007) 1.02
Cell-permeable peptide Tat-PSD-95 PDZ2 inhibits chronic inflammatory pain behaviors in mice. Mol Ther (2008) 1.02
Design and synthesis of highly potent and plasma-stable dimeric inhibitors of the PSD-95-NMDA receptor interaction. Angew Chem Int Ed Engl (2009) 0.97
Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem (2008) 0.96
Bivalent peptides as models for multimeric targets of PDZ domains. Chembiochem (2007) 0.95
Creating conformational entropy by increasing interdomain mobility in ligand binding regulation: a revisit to N-terminal tandem PDZ domains of PSD-95. J Am Chem Soc (2009) 0.94
MAGUK proteins: new targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol (2008) 0.93
Perturbing PSD-95 interactions with NR2B-subtype receptors attenuates spinal nociceptive plasticity and neuropathic pain. Mol Ther (2011) 0.92
Deciphering the kinetic binding mechanism of dimeric ligands using a potent plasma-stable dimeric inhibitor of postsynaptic density protein-95 as an example. J Biol Chem (2010) 0.87
Cell-permeable and plasma-stable peptidomimetic inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem (2011) 0.87
A cyclic peptide targeted against PSD-95 blocks central sensitization and attenuates thermal hyperalgesia. Neuroscience (2010) 0.85
Natural RNA circles function as efficient microRNA sponges. Nature (2013) 8.93
The abscisic acid receptor PYR1 in complex with abscisic acid. Nature (2009) 3.12
SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev (2011) 3.03
Structure of the Escherichia coli ribosomal termination complex with release factor 2. Nature (2003) 2.54
A cryo-electron microscopic study of ribosome-bound termination factor RF2. Nature (2003) 2.42
Structure of an intermediate state in protein folding and aggregation. Science (2012) 2.24
Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice. J Neuroinflammation (2008) 1.92
Upgraded ESRF BM29 beamline for SAXS on macromolecules in solution. J Synchrotron Radiat (2013) 1.87
Full-length extracellular region of the var2CSA variant of PfEMP1 is required for specific, high-affinity binding to CSA. Proc Natl Acad Sci U S A (2010) 1.73
Structural basis of dcp2 recognition and activation by dcp1. Mol Cell (2008) 1.65
Probing chemical shifts of invisible states of proteins with relaxation dispersion NMR spectroscopy: how well can we do? J Am Chem Soc (2008) 1.64
Modulation of the dimer interface at ionotropic glutamate-like receptor delta2 by D-serine and extracellular calcium. J Neurosci (2009) 1.63
Structural insights into eRF3 and stop codon recognition by eRF1. Genes Dev (2009) 1.57
A helical structural nucleus is the primary elongating unit of insulin amyloid fibrils. PLoS Biol (2007) 1.56
The SAXS solution structure of RF1 differs from its crystal structure and is similar to its ribosome bound cryo-EM structure. Mol Cell (2005) 1.53
Reduced proliferative capacity of hematopoietic stem cells deficient in Hoxb3 and Hoxb4. Mol Cell Biol (2003) 1.50
Location of the antidepressant binding site in the serotonin transporter: importance of Ser-438 in recognition of citalopram and tricyclic antidepressants. J Biol Chem (2009) 1.46
Structure and interactions of NCAM Ig1-2-3 suggest a novel zipper mechanism for homophilic adhesion. Structure (2003) 1.45
Demonstration of long-range interactions in a PDZ domain by NMR, kinetics, and protein engineering. Structure (2006) 1.41
Ionotropic glutamate-like receptor delta2 binds D-serine and glycine. Proc Natl Acad Sci U S A (2007) 1.36
High-throughput small angle X-ray scattering from proteins in solution using a microfluidic front-end. Anal Chem (2008) 1.36
Reassessing a sparse energetic network within a single protein domain. Proc Natl Acad Sci U S A (2008) 1.33
Mutational mapping and modeling of the binding site for (S)-citalopram in the human serotonin transporter. J Biol Chem (2009) 1.33
Low-resolution structure of a vesicle disrupting α-synuclein oligomer that accumulates during fibrillation. Proc Natl Acad Sci U S A (2011) 1.29
Simulation and experiment conspire to reveal cryptic intermediates and a slide from the nucleation-condensation to framework mechanism of folding. J Mol Biol (2005) 1.27
Dominating IgE-binding epitope of Bet v 1, the major allergen of birch pollen, characterized by X-ray crystallography and site-directed mutagenesis. J Immunol (2003) 1.25
Identification of a small-molecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD. Proc Natl Acad Sci U S A (2009) 1.23
Crystal structure of the kainate receptor GluR5 ligand-binding core in complex with (S)-glutamate. FEBS Lett (2005) 1.22
Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. Chem Commun (Camb) (2009) 1.21
Crystal structure and mechanism of activation of TANK-binding kinase 1. Cell Rep (2013) 1.19
Helical propensity in an intrinsically disordered protein accelerates ligand binding. Angew Chem Int Ed Engl (2014) 1.16
Fibroblast growth factors share binding sites in heparan sulphate. Biochem J (2005) 1.15
Full domain closure of the ligand-binding core of the ionotropic glutamate receptor iGluR5 induced by the high affinity agonist dysiherbaine and the functional antagonist 8,9-dideoxyneodysiherbaine. J Biol Chem (2009) 1.13
Nitrocellulose filter binding to assess binding of glycosaminoglycans to proteins. Methods Enzymol (2003) 1.11
Transient structure and dynamics in the disordered c-Myc transactivation domain affect Bin1 binding. Nucleic Acids Res (2012) 1.10
Comparison of successive transition states for folding reveals alternative early folding pathways of two homologous proteins. Proc Natl Acad Sci U S A (2008) 1.10
A spring-loaded release mechanism regulates domain movement and catalysis in phosphoglycerate kinase. J Biol Chem (2011) 1.10
Competitive antagonism of AMPA receptors by ligands of different classes: crystal structure of ATPO bound to the GluR2 ligand-binding core, in comparison with DNQX. J Med Chem (2003) 1.10
Single molecule unfolding and stretching of protein domains inside a solid-state nanopore by electric field. Sci Rep (2013) 1.09
Unique structure of iC3b resolved at a resolution of 24 Å by 3D-electron microscopy. Proc Natl Acad Sci U S A (2011) 1.09
Relaxation dispersion NMR spectroscopy as a tool for detailed studies of protein folding. Biophys J (2009) 1.07
Structural and functional insights into a dodecameric molecular machine - the RuvBL1/RuvBL2 complex. J Struct Biol (2011) 1.07
A PDZ domain recapitulates a unifying mechanism for protein folding. Proc Natl Acad Sci U S A (2006) 1.06
Inhibitors of histone demethylases. Bioorg Med Chem (2011) 1.06
Investigating the structural plasticity of a cytochrome P450: three-dimensional structures of P450 EryK and binding to its physiological substrate. J Biol Chem (2009) 1.06
Glyceraldehyde-3-phosphate dehydrogenase versus toluidine blue as a marker for infarct volume estimation following permanent middle cerebral artery occlusion in mice. Exp Brain Res (2006) 1.05
The structure of a mixed GluR2 ligand-binding core dimer in complex with (S)-glutamate and the antagonist (S)-NS1209. J Mol Biol (2006) 1.04
Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters. Proc Natl Acad Sci U S A (2011) 1.04
The transition state structure for coupled binding and folding of disordered protein domains. Sci Rep (2013) 1.04
A sequential binding mechanism in a PDZ domain. Biochemistry (2009) 1.03
A conserved folding mechanism for PDZ domains. FEBS Lett (2007) 1.03
The kinetics of PDZ domain-ligand interactions and implications for the binding mechanism. J Biol Chem (2005) 1.03
Identification and characterization of protein folding intermediates. Biophys Chem (2007) 1.03
Structural and functional insights into endoglin ligand recognition and binding. PLoS One (2012) 1.02
Biosynthetic 13C labeling of aromatic side chains in proteins for NMR relaxation measurements. J Am Chem Soc (2006) 1.02
Intersubunit bridge formation governs agonist efficacy at nicotinic acetylcholine α4β2 receptors: unique role of halogen bonding revealed. J Biol Chem (2011) 1.02
Fast association and slow transitions in the interaction between two intrinsically disordered protein domains. J Biol Chem (2012) 1.02
Structural determinants of agonist-specific kinetics at the ionotropic glutamate receptor 2. Proc Natl Acad Sci U S A (2005) 1.02
Interaction of antidepressants with the serotonin and norepinephrine transporters: mutational studies of the S1 substrate binding pocket. J Biol Chem (2012) 1.01
Time-resolved SAXS measurements facilitated by online HPLC buffer exchange. J Synchrotron Radiat (2010) 1.00
The binding mechanisms of intrinsically disordered proteins. Phys Chem Chem Phys (2013) 1.00
The crystal structure of recombinant proDer p 1, a major house dust mite proteolytic allergen. J Immunol (2005) 1.00
Two conserved residues govern the salt and pH dependencies of the binding reaction of a PDZ domain. J Biol Chem (2006) 1.00
From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: synthesis and structure-activity relationship studies. J Med Chem (2008) 1.00
Structural proof of a dimeric positive modulator bridging two identical AMPA receptor-binding sites. Chem Biol (2007) 1.00
Sequence-specific long range networks in PSD-95/discs large/ZO-1 (PDZ) domains tune their binding selectivity. J Biol Chem (2011) 0.99
Crystal structure of the covalent intermediate of amylosucrase from Neisseria polysaccharea. Biochemistry (2004) 0.98
Crystal structure of Lymnaea stagnalis AChBP complexed with the potent nAChR antagonist DHβE suggests a unique mode of antagonism. PLoS One (2012) 0.98
Changes in brain levels of N-acylethanolamines and 2-arachidonoylglycerol in focal cerebral ischemia in mice. J Neurochem (2007) 0.98
Water-molecule network and active-site flexibility of apo protein tyrosine phosphatase 1B. Acta Crystallogr D Biol Crystallogr (2004) 0.97
Design and synthesis of highly potent and plasma-stable dimeric inhibitors of the PSD-95-NMDA receptor interaction. Angew Chem Int Ed Engl (2009) 0.97